Skip to content Skip to Search
Skip navigation

Mubadala to buy pharma company Kelix Bio

By Pramod Kumar
The acquisition of Kelix bio is set to boost the UAE’s global standing in life sciences, said Mubadala Kelix Bio
The acquisition of Kelix bio is set to boost the UAE’s global standing in life sciences, said Mubadala

Abu Dhabi’s Mubadala Investment Company has signed a definitive agreement to acquire Kelix Bio, a specialty pharmaceutical business in the UAE that focuses on delivering complex generics across emerging markets.

The Kelix Bio acquisition is set to boost the UAE’s global standing in life sciences, state-own Abu Dhabi Media Office reported, quoting a Mubadala statement.

Person, Electronics, Mobile Phone

Newsletter
Get the Best of AGBI delivered straight to your inbox every week

The stake was purchased from a consortium of investors, including Development Partners International, the UK’s development finance institution and impact investor British International Investment, and the European Bank for Reconstruction and Development.

No financial details were shared. The transaction is subject to regulatory approvals.

Kelix Bio was founded in November 2020 and has since acquired manufacturing businesses in India, Egypt, Malta and Morocco.

It has commercialised a wide range of oral and injectable formulations for diverse therapy areas, including diabetes, oncology, cardiology and central nervous systems.

Dr Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform, said the purchase would advance Mubadala’s position in the life sciences sector and deliver long-term socio-economic returns, including improved healthcare, drug security, job creation and GDP impact.

According to research from investment banking advisory firm Alpen Capital, healthcare spending in the GCC region is set to reach $135.5 billion in 2027, implying annual growth of 5 percent from $104 billion last year.

Latest articles

OQBI has offloaded 49% of its shares, with 40% going to retail investors

Oman’s OQBI poised to make Muscat bourse debut

Oman’s OQ Base Industries will debut on Muscat’s bourse on December 15 after the state oil company subsidiary completed a $489 million initial public offering. OQBI, the third OQ unit to float since March 2023, has offloaded 49 percent of its shares. Of the shares sold, 30 percent went to institutions, 40 percent to retail […]

Turkish arms exports

Turkish arms exports up 19% year on year

Turkish defence companies have posted another record-breaking year for exports, with a 19 percent increase year on year and sales to 178 countries. Sales from January to November this year have already eclipsed 2023’s total of arms and equipment shipments to overseas clients, reflecting the arms industry’s technical developments and broader product range.  Defence and […]

Dubai Duty Free said that the sales performance was strong in November despite tough trading conditions

Perfume sales propel Dubai Duty Free to $2bn 2024 target

Dubai Duty Free (DDF) recorded sales of AED7.13 billion ($1.94 billion) in the first 11 months of 2024, as it closes in on the $2 billion annual target. The airport retailer reported sales of $205.7 million last month, marking the fifth-best month ever, propelled mainly by perfume sales, the UAE state-run Wam news agency reported. […]

A view of the Almoosa Rehabilitation Hospital. The hospital operator will divest 13.3 million shares in its IPO

Almoosa Health to raise up to $450m from Saudi IPO

Almoosa Health Company expects to raise between SAR1.63 billion and SAR1.69 billion ($433.80-449.7 million) from its initial public offering (IPO) on the Saudi stock exchange. The company set the offering price range between SAR123.00 and SAR127.00 per share as the institutional book-building period started on Wednesday and will end on December 10. The offer price […]